SOURCE: Streetwise Reports

Streetwise Reports

September 10, 2015 09:00 ET

iBio's Robert Erwin Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - September 10, 2015) - The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.'s (NYSE MKT: IBIO) iBioLaunch technology, can increase yields quickly, safely and inexpensively. In this interview with The Life Sciences Report, iBio's President Robert L. (Bob) Erwin describes the iBioLaunch technology and what it offers to drug developers and investors.

The Life Sciences Report: What's unique about iBio Inc.'s iBioLaunch technology?

Bob Erwin: Our iBioLaunch technology turns plants into protein factories without altering the plants' DNA. It is an alternate method of producing recombinant proteins for a variety of applications, but particularly for pharmaceutical use.

There have been many approaches to producing recombinant proteins using many different types of hosts, cells and tissues. Plants grown efficiently in modern hydroponic facilities offer a very attractive, economical alternative to those approaches and to traditional vat fermentation methods.

Plant cells are far more like human cells than many people realize. They can process genes much like human cells…

Continue reading this interview: The Promise of Plants in Pharmaceutical Production: iBio's Robert Erwin

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.


iBio Inc. paid Streetwise Reports to conduct, produce and distribute the interview. Mr. Erwin had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Erwin and not of The Life Sciences Report or its officers.

Contact Information